Advancing Collaborative Multiple Myeloma Care Coordination Among Oncology Centers

Intended Audience: Hematologists, Oncologists, and their teams of PAs, NPs, Nurses, and Pharmacists who care for patients with MM

Providers caring for patients with multiple myeloma (MM) face unique challenges as they sequence multiple lines of therapy and coordinate care between community oncology clinics and large academic centers.

Tune into this research-informed video to hear compelling case-based discussions of the latest clinical evidence and expert strategies for optimal collaborative care from a community and academic MM provider.

In this 1-hour video, expert faculty will review survey data completed by academic and community hematology/oncology providers and patients with MM to identify alignments and discordances in knowledge, communication, and shared decision-making to inform individualized, evidence-based treatment plans. Strategies to overcome identified barriers and discordances to effective communication and collaboration for MM care will be shared to adopt in your clinical practice.

• Evaluate current practice patterns and barriers to evidence-based treatment and management use throughout the disease course in multiple myeloma (MM)
• Differentiate new and emerging therapies, including cellular therapies, for MM based on mechanism of action, clinical data regarding their safety and efficacy, and role in treatment
• Align clinical practices with current evidence and guidelines for appropriate treatment and management of MM, including sequencing of therapies, based on patient characteristics and stage of disease
• Design interprofessional strategies for effective identification and management of adverse events in oncology clinics and CAR T-cell administration centers
• Apply interprofessional team-based strategies to improve referral, treatment, communication, and care coordination between oncology clinics and CAR T-cell centers to optimize outcomes for patients with MM

PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 1.0 contact hour (which includes 0.5 hour of pharmacology).

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

• M. Sarfraz Nawaz, MD (Speaker)
  
  Speakers Bureau or other Promotional Education – Bristol-Myers Squibb
  The relationships reported above are related to the following therapeutic area: Oncology
• Sikander Ailawadhi, MD (Speaker)
  
  Advisory Board or Panel – AbbVie, Amgen, Beigene, Bristol-Myers Squibb, Cellectar, GlaxoSmithKline, Janssen, Pfizer, Regeneron
  Consultant – Beigene, Regeneron
  Grants / Research Support – AbbVie, Ascentage, AstraZeneca, Bristol-Myers Squibb, Cellectar, GlaxoSmithKline, Janssen, Pfizer, Regeneron
  The relationships reported above are related to the following therapeutic area: Hematology-Oncology

The following individuals have no relevant financial relationships with ineligible companies to disclose:

• Jason Welch, MD (Reviewer)
• Stephanie Joyce, PA, MSPAS, MS, RD CNSC (Planner)
• Lisa Wakefield, MSN, APRN, FNP-BC (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.